Frontiers in Adjuvant Therapy in Stage II-III Melanoma

Eggermont A.M.M. : Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Rec Res Cancer Res, 157: 178–189, 2000.

Livingston P.O. , Wong G.Y.C. , Adluri S. , Toa Y. , Padavan M. , Parente R. , Hanlon C. , Calves M.J. , Helling F. , Ritter G. , Oettgen H.F. , Old L.J. : Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol, 12: 1036–1044, 1994.

Meyskens F.L. , Kopecky KJ , Taylor C.W. , Noyes R.D. , Tuthill R J. , Hersh E.M. , Feun L.G. , Doroshow J.H. , Flaherty L.E. , Sondak V.K. : Randomized trial of adjuvant human interferon-gamma versus observation in high risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst, 87: 1710–1713, 1995.

Kleeberg U. , Broecker E.B. , Lejeune F. , Chartier C. , Egger C. , Marsden J. , Ruiter D.J. , Suciu S. : EORTC 18871 adjuvant trial in high risk melanoma patients: IFNalpha vs IFNgamma vs Iscador vs observation. Eur J Cancer, 35 (Suppl 4): 264(ab-str), 1999.

Eggermont A.M.M. , Kleeberg U.R. , Ruiter D.J. , Suciu S. : European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b. In: ASCO Educational Book, pp 88–93, 2001.

Hauschild A. , Burg G. , Dummer R. : Prospective randomized multicenter trial on the oupatient use of subcutaneous inter-leukin2 and interferon a2b in high risk melanoma patients. Melanoma Res, 7 (Suppl 1): 401 (abstr), 1997.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. , Smith T.J. , Borden E.C. , Blum R.H. : Interferon-a2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol, 14: 7–17, 1996.

Creagan E.T. , Dalton R.J. , Ahmann D.L. , Noyes R.D. , Tuthill R.J. , Hersh E.M. , Feun L.G. , Doroshow J.H. , Flaherty L.E. , Sondak V.K. : Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol, 13: 2776–2783, 1995.

Kirkwood J.M. , Ibrahim J.G. , Sondak V.K. , Richards J. , Flaherty J.E. , Ernstoff M.S. , Smith T.J. , Rao U. , Steele M. , Blum R.H. : High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol, 18: 2444–2459, 2000.

Kirkwood J.M. , Ibrahim J. , Sondak V.K. , Sosman J.A. , Ernstoff M.S. : Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha 2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenies) for high-risk resected stage IIB-III melanoma: results of the Intergroup Phase III study E-1694/S9512/C503801. Ann Oncol, 11 (Suppl 4): 4(50).

Cascinelli N. : Evaluation of efficacy of adjuvant rIFNa 2A in regional node metastases. Proc Am Soc Clin Oncol, 14: 410 (abstr), 1995.

Cameron D.A. , Cornbleet M.C. , MacKie R.M. , Hunter J.A.A. , Gore M. , Hancock B. , Smyth J.F. : Adjuvant interferon alpha in high risk melanoma: The Scottish study. Br J Cancer 2001 (in press).

Pehamberger H. , Soyer P. , Steiner A. , Kofler R. , Binder M. , Mischer P. , Pachinger W. , Auböck J. , Fritsch P. , Kerl H. , Wolff K. : Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol, 16: 1425–1429, 1998.

Grob J.J. , Dreno B. , Chastang C. , Guillot B. , Cupissol B. , Souteyrand P. , Sassolas B. , Cesarini J.P. , Thivolet J. , Denoeux J.P. , Ortonne J.P. , Thomas T. , Beylot C. , Truchetet F. , Lorette G. , Chemaly C. , Meynadier J. , Amblard P. , Thyss P. , Avril M.F. , Prigent F. , Bonerandi J.J. : Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet, 351: 1905–1910, 1998.

Gershenwald J.E. , Thompson W. , Mansfield P.E. , Lee J.E. , Colome M.I. , Tcheng C-H , Balch C.M. , Reintgen D.S. , Ross M.I. : Multi-institutional melanoma lymphatic mapping experience: value of sentinel lymph node status in 612 stage I or stage II melanoma patients. J Clin Oncol, 17: 976–983, 1999.

Dinney C.P. , Bielenberg D.R. , Perrotte P. , Reich R. , Bucana C.D. , Fidler I.J. : Inhibition of basic fibroblast growth factor expression, angiogenesis and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res, 58: 808–811, 1998.

Singh R.K. , Gutman M. , Bucana C.D. , Sanchez R. , Llansa N. , Fidler I.J. : Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA, 92: 4562–4566, 1995.

Shivers S.C. , Wang X. , Li W. , Joseph E. , Messina J. , Glass L.F. , DeConti R. , Cruse C.W. , Berman C. , Fenske N.A. , Lyman G.H. , Reintgen D.S. : Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA, 28: 1410–1415, 1998.

Morton D.L. , Hoon D.S.B. , Nizze J.A. , Foshag L.J. , Famatiga E. , Wanek L.A. , Chang C. , Irie R.F. , Gupta R.K. , Elashoff R. : Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci, 690: 120–124, 1993.